BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 24614626)

  • 1. Sequential cohort design applying propensity score matching to analyze the comparative effectiveness of atorvastatin and simvastatin in preventing cardiovascular events.
    Helin-Salmivaara A; Lavikainen P; Aarnio E; Huupponen R; Korhonen MJ
    PLoS One; 2014; 9(3):e90325. PubMed ID: 24614626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Population-Based Cohort Study on the Drug-Specific Effect of Statins on Sepsis Outcome.
    Lee CC; Lee MG; Hsu TC; Porta L; Chang SS; Yo CH; Tsai KC; Lee M
    Chest; 2018 Apr; 153(4):805-815. PubMed ID: 28962887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular and economic outcomes after initiation of atorvastatin versus simvastatin in an employed population stratified by cardiovascular risk.
    Simpson RJ; Signorovitch J; Ramakrishnan K; Ivanova J; Birnbaum H; Kuznik A
    Am J Ther; 2011 Nov; 18(6):436-48. PubMed ID: 20802306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug utilization patterns and cardiovascular outcomes in elderly patients newly initiated on atorvastatin or simvastatin.
    Swindle JP; Potash J; Kulakodlu M; Kuznik A; Buikema A
    Am J Geriatr Pharmacother; 2011 Dec; 9(6):471-82. PubMed ID: 22019005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of cost-effectiveness of simvastatin versus atorvastatin in the secondary prevention of cardiovascular events within the Brazilian public healthcare system].
    Araujo DV; Ribeiro de Souza CP; Bahia LR; Rey HC; Dos Santos Junior B; Tura BR; Berwanger O; Buehler AM; Silva MT
    Value Health; 2011; 14(5 Suppl 1):S29-32. PubMed ID: 21839894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study.
    Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
    Curr Med Res Opin; 2008 Jul; 24(7):1987-2000. PubMed ID: 18554430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of cardiovascular event rates in patients without cardiovascular disease in whom atorvastatin or simvastatin was newly initiated.
    Jacobson TA; Wertz DA; Hoy T; Kuznik A; Grochulski D; Cziraky M
    Mayo Clin Proc; 2008 Dec; 83(12):1316-25. PubMed ID: 19046550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Propensity score estimation to address calendar time-specific channeling in comparative effectiveness research of second generation antipsychotics.
    Dusetzina SB; Mack CD; Stürmer T
    PLoS One; 2013; 8(5):e63973. PubMed ID: 23667693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cost-effectiveness of rosuvastatin versus simvastatin, atorvastatin and pitavastatin in patients with high and very high cardiovascular risk in Spain].
    Cosin Sales J; Fuentes Jiménez FJ; Mantilla Morató T; Ruiz E; Becerra V; Aceituno S; Ferrario MG; Lizán L; Gracia A
    Clin Investig Arterioscler; 2015; 27(5):228-38. PubMed ID: 25640158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
    Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
    Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom.
    Cao X; Ejzykowicz F; Ramey DR; Sajjan S; Ambegaonkar BM; Mavros P; Tunceli K
    Clin Ther; 2015 Apr; 37(4):804-15. PubMed ID: 25626487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population.
    Simpson RJ; Signorovitch J; Birnbaum H; Ivanova J; Connolly C; Kidolezi Y; Kuznik A
    Mayo Clin Proc; 2009 Dec; 84(12):1065-72. PubMed ID: 19955243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men.
    Peura P; Martikainen J; Soini E; Hallinen T; Niskanen L
    Curr Med Res Opin; 2008 Jun; 24(6):1823-32. PubMed ID: 18485270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A large observational study of cardiovascular outcomes associated with atorvastatin or simvastatin therapy in hypertensive patients without prior cardiovascular disease.
    Foody JM; Joyce AT; Jeffers BW; Liu LZ; Benner JS
    Am J Ther; 2011; 18(2):110-6. PubMed ID: 20216383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
    Pedersen TR; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Holme I; Larsen ML; Bendiksen FS; Lindahl C; Szarek M; Tsai J;
    JAMA; 2005 Nov; 294(19):2437-45. PubMed ID: 16287954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of atorvastatin over the product life cycle in the United States.
    Grabner M; Johnson W; Abdulhalim AM; Kuznik A; Mullins CD
    Clin Ther; 2011 Oct; 33(10):1433-43. PubMed ID: 21955936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of statins in secondary prevention among the older people aged 75 years and over.
    Kwak A; Kim JH; Choi CU; Kim IW; Oh JM; Kim K
    Int J Clin Pharm; 2019 Apr; 41(2):460-469. PubMed ID: 30864086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.
    Plosker GL; Lyseng-Williamson KA
    Pharmacoeconomics; 2007; 25(12):1031-53. PubMed ID: 18047388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statin prescribing in the elderly in the Netherlands: a pharmacy database time trend study.
    Geleedst-De Vooght M; Maitland-van der Zee AH; Schalekamp T; Mantel-Teeuwisse A; Jansen P
    Drugs Aging; 2010 Jul; 27(7):589-96. PubMed ID: 20583852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.
    Ohsfeldt RL; Gandhi SK; Fox KM; Stacy TA; McKenney JM
    Am J Manag Care; 2006 Nov; 12(15 Suppl):S412-23. PubMed ID: 17112329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.